SenoScan clears FDA
Customers shopping for full-field digital mammography systems have another product to consider. The FDA has cleared Fischer Imaging’s SenoScan for sale in the U.S. In making the announcement Sept. 25, Fischer executives predicted that a large
Customers shopping for full-field digital mammography systems have another product to consider. The FDA has cleared Fischer Imaging’s SenoScan for sale in the U.S. In making the announcement Sept. 25, Fischer executives predicted that a large portion of the currently installed 30,000 screen-film mammography systems would eventually be replaced by digital systems, with the conversion rate reaching as high as 1500 systems per year by 2007. So far, only Fischer and GE Medical Systems have been cleared to sell such products. Prior to the FDA decision, Fischer announced the sale of five SenoScans to research institutions participating in a $26 million study sponsored by the National Cancer Institute to determine the accuracy of digital mammography. SenoScan, which is built around a slot scanning digital detector, can support computer-aided detection software, tomosynthesis involving 3-D imaging, and contrast subtraction mammography.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
